Stable protein solution formulation containing high concentration of an anti-VEGF antibody
US10689438B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 6, 2015 |
| Grant date | Jun 23, 2020 |
| Priority date | — |
| Expiry date | Jun 29, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.